Sciex, A*STAR to collaborate on advance biologics research & development in Singapore

1 February 2016

Research services company Sciex said it has signed a biologics research and development collaboration with Bioprocessing Technology Institute (BTI), a research institute under Singapore's Agency for Science, Technology and Research (A*STAR).

Under the terms of the deal, Sciex will provide BTI with its reliable, sensitive and intuitive instruments including the TripleTOF 6600 system and a Nano LC system, along with Sciex software, and support from a team of application experts to assist with the analysis of complex contaminant protein molecules related to the production and analysis of biologic drugs.

No financial details were disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK